GLAXO — GlaxoSmithKline Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00
- IN₹360.61bn
- IN₹343.61bn
- IN₹32.52bn
C2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 6,540 | 6,472 | 7,231 | 7,675 | 8,374 |
Depreciation | |||||
Non-Cash Items | -889 | -976 | -1,233 | -243 | -1,085 |
Discontinued Operations | |||||
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -2,042 | -1,418 | -1,012 | -6.37 | -3,105 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 4,095 | 4,905 | 5,779 | 8,107 | 4,842 |
Capital Expenditures | -2,913 | -1,584 | -442 | -346 | -440 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 1,378 | 1,015 | 4,628 | -3,709 | 8,519 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -1,535 | -568 | 4,186 | -4,055 | 8,079 |
Financing Cash Flow Items | -615 | -738 | -35.3 | -19.9 | -9.55 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -3,584 | -4,276 | -6,961 | -5,242 | -15,433 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -1,023 | 60.3 | 3,004 | -1,190 | -2,512 |